替罗非班治疗急性冠脉综合征临床观察

Clinical investigation of tirofiban in treatment of acute coronary syndrome

目的观察血小板GPⅡb/Ⅲa受体拮抗剂替罗非班治疗急性冠脉综合征(ACS)的临床效果和安全性。方法70例急性冠脉综合征患者随机、双盲分为替罗非班静脉应用组(n=35)与常规治疗组(n=35),疗程36h,终点事件是36h和30天的复合缺血事件(死亡、新发心肌梗死、顽固心肌缺血)。结果36h及30天的复合缺血事件发生率,受试组低于对照组(36h:2.9%vs22.9%,30天:5.7%vs35.7%,P<0.001),替罗非班组肌钙蛋白T(cTnT)峰值水平明显低于对照组,出血并发症在两组之间差异无显著性(P>0.05)。结论替罗非班在ACS标准治疗基础上能进一步减少心肌缺血事件,并能减少心肌细胞的损伤,且安全性较好。

Objective To evaluate the efficacy and safety of tirofiban In treatment of acute coronary syndrome （ACS） among Chinese people. Methods Seventy patients were randomly assigned in a double - blind manner to receive triofiban plus LMWCH or placebo plus LMWF alone for 36 hours. The composite end point events consisted of death, myocardial infarction, or refractory ischaemic with in 36 hours and 30 days after randomization. Results The frequency of the composite primary end point events at 36 hours and 30 days were lower among the patients who received tirofiban plus LMWF than those who received LMWF plus placebo（2.9% vs22.9% ）2（5.7% vs35.7% P 〈 0. 001 ） , cTnT in tirofiban group were obviously lower than those in the LMEF plus placebo group. Bleeding are not significant different between two groups. Conclusion Tirofiban may further lower the incidence of ischemic events safely in patients with acute coronary syndrome on the basis of standard treatments in ACS.